Literature DB >> 24330903

Efficacy and cognitive side effects after brief pulse and ultrabrief pulse right unilateral electroconvulsive therapy for major depression: a randomized, double-blind, controlled study.

Harm-Pieter Spaans1, Esmée Verwijk, Hannie C Comijs, Rob M Kok, Pascal Sienaert, Filip Bouckaert, Katrien Fannes, Koen Vandepoel, Erik J A Scherder, Max L Stek, King H Kho.   

Abstract

OBJECTIVE: To compare the efficacy and cognitive side effects of high-dose unilateral brief pulse electroconvulsive therapy (ECT) with those of high-dose unilateral ultrabrief pulse ECT in the treatment of major depression.
METHOD: From April 2007 until March 2011, we conducted a prospective, double-blind, randomized multicenter trial in 3 tertiary psychiatric hospitals. All patients with a depressive disorder according to DSM-IV criteria were eligible. Depression severity was assessed with the Montgomery-Asberg Depression Rating Scale; primary efficacy outcomes were response, defined as a score decrease ≥ 60% from baseline, and remission, defined as a score < 10 at 2 consecutive weekly assessments. Total scores on the Autobiographical Memory Interview and Amsterdam Media Questionnaire were the primary outcome measures for retrograde amnesia. Other cognitive domains included category fluency (semantic memory) and letter fluency (lexical memory). Patients received twice-weekly unilateral brief pulse (1.0 millisecond) or ultrabrief pulse (0.3-0.4 millisecond) ECT 8 times seizure threshold until remission, for a maximum of 6 weeks.
RESULTS: Of the 116 patients, 75% (n = 87) completed the study. Among completers, 68.4% (26/58) of those in the brief pulse group achieved remission versus 49.0% (24/49) of those in the ultrabrief pulse group (P = .019), and the brief pulse group needed fewer treatment sessions to achieve remission: mean (SD) of 7.1 (2.6) versus 9.2 (2.3) sessions (P = .008). No significant group differences were found in the evaluation of the cognitive assessments.
CONCLUSIONS: The efficacy and speed of remission seen with high-dose brief pulse right unilateral ECT twice weekly were superior to those seen with high-dose ultrabrief pulse right unilateral ECT, with equal cognitive side effects as defined by retrograde amnesia, semantic memory, and lexical memory. TRIAL REGISTRATION: Netherlands National Trial Register number: NTR1304. © Copyright 2013 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24330903     DOI: 10.4088/JCP.13m08538

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  17 in total

1.  A Review of Brain Stimulation Treatments for Late-Life Depression.

Authors:  Daniel M Blumberger; Jonathan H Hsu; Zafiris J Daskalakis
Journal:  Curr Treat Options Psychiatry       Date:  2015-09-28

2.  Short- and Long-term Cognitive Outcomes in Patients With Major Depression Treated With Electroconvulsive Therapy.

Authors:  Megha M Vasavada; Amber M Leaver; Stephanie Njau; Shantanu H Joshi; Linda Ercoli; Gerhard Hellemann; Katherine L Narr; Randall Espinoza
Journal:  J ECT       Date:  2017-12       Impact factor: 3.635

Review 3.  Neuromodulation therapies for geriatric depression.

Authors:  Verònica Gálvez; Kerrie-Anne Ho; Angelo Alonzo; Donel Martin; Duncan George; Colleen K Loo
Journal:  Curr Psychiatry Rep       Date:  2015-07       Impact factor: 5.285

4.  Right Unilateral Ultrabrief Pulse ECT in Geriatric Depression: Phase 1 of the PRIDE Study.

Authors:  Charles H Kellner; Mustafa M Husain; Rebecca G Knapp; W Vaughn McCall; Georgios Petrides; Matthew V Rudorfer; Robert C Young; Shirlene Sampson; Shawn M McClintock; Martina Mueller; Joan Prudic; Robert M Greenberg; Richard D Weiner; Samuel H Bailine; Peter B Rosenquist; Ahmad Raza; Styliani Kaliora; Vassilios Latoussakis; Kristen G Tobias; Mimi C Briggs; Lauren S Liebman; Emma T Geduldig; Abeba A Teklehaimanot; Sarah H Lisanby
Journal:  Am J Psychiatry       Date:  2016-07-15       Impact factor: 18.112

5.  Grey matter volume increase following electroconvulsive therapy in patients with late life depression: a longitudinal MRI study.

Authors:  Filip Bouckaert; François-Laurent De Winter; Louise Emsell; Annemieke Dols; Didi Rhebergen; Martien Wampers; Stefan Sunaert; Max Stek; Pascal Sienaert; Mathieu Vandenbulcke
Journal:  J Psychiatry Neurosci       Date:  2016-03       Impact factor: 6.186

6.  Brief vs. ultrabrief pulse ECT: focus on seizure quality.

Authors:  Isabelle Brunner; Michael Grözinger
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2018-07-18       Impact factor: 5.270

7.  A novel Seizure Quality Index based on ictal parameters for optimizing clinical decision making in electroconvulsive therapy. Part 1: development.

Authors:  Laura Kranaster; Suna Su Aksay; Jan Malte Bumb; Carolin Hoyer; Christine Jennen-Steinmetz; Alexander Sartorius
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2018-06-06       Impact factor: 5.270

8.  A two-site, open-label, non-randomized trial comparing Focal Electrically-Administered Seizure Therapy (FEAST) and right unilateral ultrabrief pulse electroconvulsive therapy (RUL-UBP ECT).

Authors:  Gregory L Sahlem; William V McCall; E Baron Short; Peter B Rosenquist; James B Fox; Nagy A Youssef; Andrew J Manett; Suzanne E Kerns; Morgan M Dancy; Laryssa McCloud; Mark S George; Harold A Sackeim
Journal:  Brain Stimul       Date:  2020-07-29       Impact factor: 8.955

9.  Brief pulse and ultrabrief pulse right unilateral electroconvulsive therapy (ECT) for major depression: efficacy, effectiveness, and cognitive effects.

Authors:  Charles H Kellner; Shawn M McClintock; W Vaughn McCall; George Petrides; Rebecca G Knapp; Richard D Weiner; Robert C Young; Robert M Greenberg; Matthew V Rudorfer; Gabriella M Ahle; Lauren S Liebman; Sarah H Lisanby
Journal:  J Clin Psychiatry       Date:  2014-07       Impact factor: 4.384

Review 10.  Multifactorial determinants of the neurocognitive effects of electroconvulsive therapy.

Authors:  Shawn M McClintock; Jimmy Choi; Zhi-De Deng; Lawrence G Appelbaum; Andrew D Krystal; Sarah H Lisanby
Journal:  J ECT       Date:  2014-06       Impact factor: 3.635

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.